Ultragenyx Pharmaceutical Inc. - 8-K Filing
Ultragenyx's Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet primary and key secondary endpoints. (Items: 8.01 Other Events)
Tickers: $RARE
More Regulatory news
- BlueOne Technologies, Inc. - 10-Q Filing
- Newton Golf Company, Inc. - 10-Q Filing
- XBiotech Inc. - 10-Q Filing
- Cohen & Co Inc. - 10-Q Filing
- UNITED BANCORP INC /OH/ - 10-Q Filing
- PATRIOT GOLD CORP - 10-Q Filing
- First Digital Acquisition Corp Ltd. - 8-K Filing
- GROOVE BOTANICALS INC. - 10-Q Filing
- Johnson Controls International plc - 10-K Filing
- OLD NATIONAL BANCORP /IN/ - 8-K Filing